Create an account
Blocks platelet COX-1 (TXA2 synthesis) irreversibly and inhibits platelet aggregation. Used for prophylaxis for of clotting (strokes, MIs) and for acute MIs. Should be avoided in patients with active peptic ulcer, hepatic or renal disease, disorders of coagulation.
-Platelet ADP RECEPTOR ANTAGONIST
-Oral, 2 step biotransformation
-Bone marrow toxicity, aplastic anemia, thrombotic thrombocytopenic purpura
-Platelet ADP RECEPTOR ANTAGONIST
-oral, 2 step biotransformation: less effective if given with inhibitors of CYP2C19 (e.g. omeprazole)
-94% of dose is inactivated by esterases
-slight bone marrow toxicity
-Reversible ADP-RECEPTOR INHIBITOR
-Shorter onset of action (2 hrs) and half life (1 day) vs clopidogrel (4 hr, 3 day)
-Human/mouse chimeric Fab fragment against the fibrin receptor (gp IIb/IIIa) that irriversible blocks the receptor, is given IV short term to prophylactically prevent clots during percutaneous coronary interventions (e.g. angioplasty)
-Administered IV to competitively INHIBIT FIBRIN RECEPTOR (Gp IIb/IIIa) on platelets. Analog to rattlesnake venom that mimmics the RGD sequence on fibrin. Used to treat acute coronary syndrome and Percutaneous coronary interventions (coronary angioplasty, stent insertion)
-IV non-peptide RGD sequence mimetic (Fibrinogen receptor [gp IIb/IIIa] antagonist) approved for treatment of unstable angina and coronary angioplasty
-Coronary VASODILATOR and ANTIPLATELET that blocks PDE (elevates cAMP) and Adenosine deaminase (elevates adenosine); used in combo with asprin as prophylaxis against TIAs
-Oral inhibitor of PDE III (elevates cAMP) used to treat intermittent claudication by INHIBITING PLATELET AGGREGATION and promoting VASODILATION
-Increases heart rate and contractility (via cAMP)
-Contraindicated in CHF patients
-Prostacyclin (PGI2) administered IV to raise cAMP and lower Ca++ in platelets to inhibit the release reaction and thus INHIBIT PLATELET aggregation
-Vasodilator primarily used for the treatment of primary pulmonary hypertension; prevents platelet aggregation in extra corporeal circulation of blood (hemodialysis)
-Side effects include a decrease in blood pressure
-Pentasaccharide that accelerates antithrombin III's inactivation of Xa but NOT THROMBIN
-Dose independent half life of 17-21 hours (renal clearance)
direct inhibitor of thrombin that is indicated for continous IV infusion for the treatment of HIT type II
A direct inhibitor of thrombin that is administered SC and indicated for DVT prophylaxis in hip replacement surgery
e-aminocaproic acid (EACA)
Plasmin inhibitor used in treatment of dental bleeding, pressure dressing, etc.
-forms a complex with free plasminogen that allows PLASMINOGEN to convert other plasminogen into plasmin
-Administered as loading dose plus contionuous IV infusion (since many people have antibodies to it)
-rtPA that activates plasminogen on the surface of fibrin on the thrombus (fibrinolytic drug); given as a continuous IV infusion
-modified tPA (fibrinolytic drug) that has a longer half life (13-16 min) and therefore given as an IV bolus (not continuous IV)
-modified tPA (fibrinolytic drug) that has a longer half life (20-24 min) and therefore given as an IV bolus (not continuous IV)
Please allow access to your computer’s microphone to use Voice Recording.
Having trouble? Click here for help.
We can’t access your microphone!
Click the icon above to update your browser permissions and try again
Reload the page to try again!Reload
Press Cmd-0 to reset your zoom
Press Ctrl-0 to reset your zoom
It looks like your browser might be zoomed in or out. Your browser needs to be zoomed to a normal size to record audio.
Please upgrade Flash or install Chrome
to use Voice Recording.
For more help, see our troubleshooting page.
Your microphone is muted
For help fixing this issue, see this FAQ.
Star this term
You can study starred terms together